PFE News Alert Pfizer Inc (PFE) 31.42 01/06/2015 18:11:04
Post# of 64200
Posted On: 01/06/2015 7:11:05 PM
Pfizer Inc (PFE) 31.42 $PFE
Most active New York Stock Exchange-traded stocks
AP - 1 hr 6 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
TLM.TO: 9.11 (+0.04), KO: 42.46 (+0.32), GE: 24.07 (-0.53), F: 14.62 (-0.14), JPM: 58.98 (-1.57), TLM: 7.71 (-0.03), S: 4.19 (-0.02), PFE: 31.42 (+0.26), C: 50.70 (-1.85), BAC: 16.86 (-0.52), TWTR: 38.76 (+2.38), RAD: 7.71 (+0.19)
Final Glance: Pharmaceuticals companies
AP - 1 hr 6 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)
Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers
at The Street - 1 hr 31 mins ago
Shire has cash for what could be a $5 billion deal, but treatment base is limited.
CBST: 100.80 (+0.12), SHPG: 207.14 (+1.09), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), NPSP: 41.06 (+2.93), ABBV: 64.33 (-0.32), HSP: 60.63 (-0.33)
Is Conatus Poised For A Breakout?
Left Banker - at Seeking Alpha - Tue Jan 06, 1:42PM CST
CNAT: 10.63 (+0.57), PFE: 31.42 (+0.26)
Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:50PM CST
Immunomedics, Inc.'s (IMMU) sacituzumab govitecan has received fast track status from the FDA for triple-negative breast cancer.
IMMU: 4.71 (-0.28), INCY: 71.49 (-2.73), PFE: 31.42 (+0.26), RGDO: 0.88 (-0.06)
Midday Glance: Pharmaceuticals companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), QCOR: 93.60 (+1.52), ISIS: 65.44 (-2.73), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), VVUS: 2.94 (-0.10), JUNO: 51.66 (+5.71), BMY: 58.48 (-0.10), MNKD: 5.57 (-0.13), ARNA: 3.32 (-0.20), PBYI: 188.12 (-0.25), CELG: 110.51 (-1.42)
Pfizer (PFE) Crosses Pivot Point Resistance at $31.38
Comtex SmarTrend(R) - Tue Jan 06, 10:39AM CST
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $31.19 today and have reached the first resistance level of $31.38. Investors may be interested in a cross of the next upside pivot targets of $31.59 and $31.99.
PFE: 31.42 (+0.26)
Why Biogen Idec Inc. Stock Catapulted 10% Higher in December
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 06, 10:31AM CST
What: Shares of Biogen Idec , a biotech juggernaut primarily focused on treating multiple sclerosis and autoimmune disorders, scorched higher by 10% in December, based on data from S&P Capital IQ , on the heels of positive clinical data...
JNJ: 103.28 (-0.51), BIIB: 334.65 (-2.09), PFE: 31.42 (+0.26), DB: 28.36 (-0.46), LLY: 69.72 (+0.35)
Dow Correction: Why This Popular Move Might Not Save You
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jan 06, 10:17AM CST
Source: Wikimedia Commons , Jean-Pierre Lavoie. Monday's 331-point plunge in the Dow Jones Industrials set investors on edge, raising fears that the 6-year-old bull market might finally be drawing to a close. In response, many nervous investors...
KO: 42.46 (+0.32), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), MCD: 92.40 (+0.17)
Early Glance: Pharmaceuticals companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Business Wire - Tue Jan 06, 9:00AM CST
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 2:30 p.m. Pacific Standard Time.
JPM: 58.98 (-1.57), PFE: 31.42 (+0.26)
Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Jan 06, 6:47AM CST
Source: Flickr via Montgomery County Planning Commission As the world's largest pharmaceutical company, Pfizer rarely inspires investors seeking high-growth opportunities. Indeed, its stock has performed rather poorly compared to the broader...
ZTS: 42.63 (-0.42), ACT: 255.17 (-1.52), AZN: 68.16 (-1.70), PFE: 31.42 (+0.26), TEVA: 54.93 (-0.16), ABBV: 64.33 (-0.32), NVS: 91.67 (-0.78), CELG: 110.51 (-1.42)
Dow Dividend Dogs: Yahoo Finds 2.83% Edge For 5 Lowest Price High Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 6:46AM CST
KO: 42.46 (+0.32), T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47)
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
PR Newswire - Tue Jan 06, 6:30AM CST
CytomX, a biotechnology company developing Probody(TM) therapeutics for the treatment of cancer, today announced that the company has raised $20 million in a Series C financing round. Pfizer Venture Investments led the round, with participation from existing investors Third Rock Ventures, Canaan Partners and the Roche Venture Fund.
PFE: 31.42 (+0.26)
Dow Dividend Dogs: Arbitrage Finds .32% Advantage For 5 Lowest-Priced, High-Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 12:21AM CST
T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01)
A Dozen Dow Dividend Dogs Dance About 9% To 20% Upsides Into January
Fredrik Arnold - at Seeking Alpha - Mon Jan 05, 11:43PM CST
KO: 42.46 (+0.32), MMM: 158.65 (-1.71), GE: 24.07 (-0.53), UNH: 98.92 (-0.20), PFE: 31.42 (+0.26), XOM: 89.81 (-0.48), BA: 127.53 (-1.52), T: 33.60 (+0.05), JPM: 58.98 (-1.57), MRK: 60.32 (+2.28), DD: 70.89 (-0.83), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), MSFT: 45.65 (-0.68), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01), TRV: 103.24 (-0.93)
Update: Pfizer Improves Prospects With Acquisition Of Redbiotec
Trevor Lowenthal - at Seeking Alpha - Mon Jan 05, 4:33PM CST
PFE: 31.42 (+0.26)
Pfizer continues vaccine push, buys Switzerland's Redvax
AP - Mon Jan 05, 12:49PM CST
NEW YORK (AP) — Pfizer continued its aggressive push into the development of new vaccines, announcing the acquisition of a controlling stake in Switzerland's Redvax GmbH on Monday.
BAX: 71.11 (-0.38), PFE: 31.42 (+0.26)
Most active New York Stock Exchange-traded stocks
AP - 1 hr 6 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
TLM.TO: 9.11 (+0.04), KO: 42.46 (+0.32), GE: 24.07 (-0.53), F: 14.62 (-0.14), JPM: 58.98 (-1.57), TLM: 7.71 (-0.03), S: 4.19 (-0.02), PFE: 31.42 (+0.26), C: 50.70 (-1.85), BAC: 16.86 (-0.52), TWTR: 38.76 (+2.38), RAD: 7.71 (+0.19)
Final Glance: Pharmaceuticals companies
AP - 1 hr 6 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)
Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers
at The Street - 1 hr 31 mins ago
Shire has cash for what could be a $5 billion deal, but treatment base is limited.
CBST: 100.80 (+0.12), SHPG: 207.14 (+1.09), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), NPSP: 41.06 (+2.93), ABBV: 64.33 (-0.32), HSP: 60.63 (-0.33)
Is Conatus Poised For A Breakout?
Left Banker - at Seeking Alpha - Tue Jan 06, 1:42PM CST
CNAT: 10.63 (+0.57), PFE: 31.42 (+0.26)
Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:50PM CST
Immunomedics, Inc.'s (IMMU) sacituzumab govitecan has received fast track status from the FDA for triple-negative breast cancer.
IMMU: 4.71 (-0.28), INCY: 71.49 (-2.73), PFE: 31.42 (+0.26), RGDO: 0.88 (-0.06)
Midday Glance: Pharmaceuticals companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), QCOR: 93.60 (+1.52), ISIS: 65.44 (-2.73), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), VVUS: 2.94 (-0.10), JUNO: 51.66 (+5.71), BMY: 58.48 (-0.10), MNKD: 5.57 (-0.13), ARNA: 3.32 (-0.20), PBYI: 188.12 (-0.25), CELG: 110.51 (-1.42)
Pfizer (PFE) Crosses Pivot Point Resistance at $31.38
Comtex SmarTrend(R) - Tue Jan 06, 10:39AM CST
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $31.19 today and have reached the first resistance level of $31.38. Investors may be interested in a cross of the next upside pivot targets of $31.59 and $31.99. PFE: 31.42 (+0.26)
Why Biogen Idec Inc. Stock Catapulted 10% Higher in December
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 06, 10:31AM CST
What: Shares of Biogen Idec , a biotech juggernaut primarily focused on treating multiple sclerosis and autoimmune disorders, scorched higher by 10% in December, based on data from S&P Capital IQ , on the heels of positive clinical data...
JNJ: 103.28 (-0.51), BIIB: 334.65 (-2.09), PFE: 31.42 (+0.26), DB: 28.36 (-0.46), LLY: 69.72 (+0.35)
Dow Correction: Why This Popular Move Might Not Save You
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jan 06, 10:17AM CST
Source: Wikimedia Commons , Jean-Pierre Lavoie. Monday's 331-point plunge in the Dow Jones Industrials set investors on edge, raising fears that the 6-year-old bull market might finally be drawing to a close. In response, many nervous investors...
KO: 42.46 (+0.32), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), MCD: 92.40 (+0.17)
Early Glance: Pharmaceuticals companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 103.28 (-0.51), BAX: 71.11 (-0.38), PFE: 31.42 (+0.26), BMY: 58.48 (-0.10)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Business Wire - Tue Jan 06, 9:00AM CST
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 2:30 p.m. Pacific Standard Time.
JPM: 58.98 (-1.57), PFE: 31.42 (+0.26)
Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Jan 06, 6:47AM CST
Source: Flickr via Montgomery County Planning Commission As the world's largest pharmaceutical company, Pfizer rarely inspires investors seeking high-growth opportunities. Indeed, its stock has performed rather poorly compared to the broader...
ZTS: 42.63 (-0.42), ACT: 255.17 (-1.52), AZN: 68.16 (-1.70), PFE: 31.42 (+0.26), TEVA: 54.93 (-0.16), ABBV: 64.33 (-0.32), NVS: 91.67 (-0.78), CELG: 110.51 (-1.42)
Dow Dividend Dogs: Yahoo Finds 2.83% Edge For 5 Lowest Price High Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 6:46AM CST
KO: 42.46 (+0.32), T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47)
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
PR Newswire - Tue Jan 06, 6:30AM CST
CytomX, a biotechnology company developing Probody(TM) therapeutics for the treatment of cancer, today announced that the company has raised $20 million in a Series C financing round. Pfizer Venture Investments led the round, with participation from existing investors Third Rock Ventures, Canaan Partners and the Roche Venture Fund.
PFE: 31.42 (+0.26)
Dow Dividend Dogs: Arbitrage Finds .32% Advantage For 5 Lowest-Priced, High-Yield January 2 Issues
Fredrik Arnold - at Seeking Alpha - Tue Jan 06, 12:21AM CST
T: 33.60 (+0.05), GE: 24.07 (-0.53), PFE: 31.42 (+0.26), MRK: 60.32 (+2.28), XOM: 89.81 (-0.48), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01)
A Dozen Dow Dividend Dogs Dance About 9% To 20% Upsides Into January
Fredrik Arnold - at Seeking Alpha - Mon Jan 05, 11:43PM CST
KO: 42.46 (+0.32), MMM: 158.65 (-1.71), GE: 24.07 (-0.53), UNH: 98.92 (-0.20), PFE: 31.42 (+0.26), XOM: 89.81 (-0.48), BA: 127.53 (-1.52), T: 33.60 (+0.05), JPM: 58.98 (-1.57), MRK: 60.32 (+2.28), DD: 70.89 (-0.83), MCD: 92.40 (+0.17), CAT: 86.47 (-0.56), CVX: 108.03 (-0.05), MSFT: 45.65 (-0.68), VZ: 47.04 (+0.47), CSCO: 27.05 (-0.01), TRV: 103.24 (-0.93)
Update: Pfizer Improves Prospects With Acquisition Of Redbiotec
Trevor Lowenthal - at Seeking Alpha - Mon Jan 05, 4:33PM CST
PFE: 31.42 (+0.26)
Pfizer continues vaccine push, buys Switzerland's Redvax
AP - Mon Jan 05, 12:49PM CST
NEW YORK (AP) — Pfizer continued its aggressive push into the development of new vaccines, announcing the acquisition of a controlling stake in Switzerland's Redvax GmbH on Monday.
BAX: 71.11 (-0.38), PFE: 31.42 (+0.26)
(0)
(0)